Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency | oneedsvoice

welcome to oneEDSvoice

- a positively charged Ehlers Danlos Syndrome community.
  • join today!
active, not recruiting

Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency

study id #: NCT00811785

condition: Menkes Disease, Occipital Horn Syndrome

status: active, not recruiting


Menkes disease and occipital horn syndrome are two forms of copper deficiency that must be diagnosed and treated very early in life to prevent serious developmental problems. However, these and other forms of copper deficiency are not very well understood, and further research is needed to determine whether certain treatments are useful in treating copper deficiency. One such treatment is copper histidine, a copper replacement that can be injected directly into the body to avoid absorption through the gastrointestinal tract. This study will investigate the effectiveness, side effects, and dosage of copper histidine treatment for patients with copper deficiency. It will also collect medical history information from patients to allow researchers to study possible genetic and nongenetic origins of copper deficiency. This study will include 100 subjects, all of whom will be children and adults who have been diagnosed with Menkes disease, occipital horn syndrome, or other unexplained copper deficiency. Patients will receive a prescribed dose of copper histidine, which will be administered daily as an injection. During the study, patients will be admitted to the NIH Clinical Center on an outpatient basis to evaluate their response to the copper histidine treatment. These evaluations will take place every 8 months, with a final evaluation performed after 3 years of treatment. During the outpatient visits, patients will be required to give blood and urine samples for testing and undergo ultrasound testing. They will also undergo brain MRI scans at the initial visit and at the 16-month and 36-month visits. Patients who agree will give additional blood samples for genetic research purposes.

intervention: Copper Histidine

start date: February 27, 2009

estimated completion: December 31, 2021

last updated: March 25, 2019

phase of development: Phase 3

size / enrollment: 93

study description: The purpose of this study is to allow currently enrolled participants to complete their three-year course of subcutaneous Copper Histidinate treatment under the protocol. We hypothesize that subcutaneous injections of this drug will raise serum copper levels and ceruloplasmin levels in enrolled participants, improve neurodevelopmental and neurological outcomes, and reduce mortality compared to untreated affected subjects.
-Primary Objective: Evaluate responses to Copper Histidinate treatment for clinical care.
-Completion of three years treatment by 13 remaining subjects
Study Population:
The 13 remaining subjects
Phase: Clinical Care/Treatment only
Description of Sites/Facilities Enrolling Participants: The study will occur at the NIH Clinical Center
Description of Study Intervention:
The study intervention is administration of Copper Histidinate in dose(s) prescribed as follows: 250 microgram sc b.i.d. in infants up to 12 months of age, and 250 microgram sc q.d. for infants and children older than 12 months. The total duration of copper histidinate treatment will not exceed three years.
Study Duration:
The estimated time from when the study opens to enrollment until completion is approximately 151 months (02/27/2009-09/30/2021). (May end sooner pending FDA new drug approval.)
Participant Duration:
The time it will take for each individual participant to complete all participant visits is approximately 36 months. There are 13 subjects with a total of 31 visits to complete.

primary outcomes:

  • Neurodevelopment [ Time Frame:Three years ]
    Study drug toxicity

secondary outcomes:

  • Survival [ Time Frame:Three years ]

inclusion criteria: -Serum copper levels less than 75 micrograms/dl

exclusion criteria: - pre-existing liver or kidney disease
- history of bleeding diatheses
- pregnancy
- diagnosis of Wilson disease
- any disease or condition that, in the opinion of the Investigator, has a high probability of precluding the patient from completing the study or where the patient cannot or will not appropriately comply with study requirements
- participation in any other investigational trial in which receipt of investigational drug or device occurred within 30 days prior to screening for this study
- history of diagnosed drug or alcohol dependence within the previous 3 years
- disease processes that may adversely affect gastrointestinal absorption
- chronic/severe cardiac disease including but not limited to cardiac insufficiency, arrhythmias, bradycardia, or hypotension, or a history of cerebrovascular accident (CVA).

sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

investigators: Stephen G Kaler, M.D.

locations: United States